Owen Mumford launches next-generation safety needle

The new, innovative device will be showcased at the 55^th European Association for the Study of Diabetes (EASD) Annual Meeting in Barcelona, where Owen Mumford will be an exhibitor.

Ateria^®SafeControl^® is an active safety pen needle for healthcare professionals (HCPs) who use injection pens to give medication, especially for diabetes patients. It is designed to help protect HCPs from needlestick injuries (NSIs) while allowing them to maintain control over the injection process.

Tracey Sainsbury, Group Product Manager at Owen Mumford, commented, “We believe that Ateria^®SafeControl^® will provide HCPs with all the benefits of a safety-engineered device, while also letting them stay in control of how medication is delivered.”

“As a company, Owen Mumford is committed to meeting the needs of HCPs and patients with medical device innovation. That’s why we’ve commissioned research and taken the time to truly understand HCPs’ daily experience and needs, and how those impact patients. This approach has driven us to create a solution that helps keep both HCPs and patients safe.”

Ateria^®SafeControl^® features and benefits:

• A visible needle for added control during injection
• An innovative manual push tab for one-handed safety activation
• Clear visual and audible safety indicators confirm when safety is engaged
• A safety shield over the needle to prevent needlestick injuries after use
• The non-patient end of the needle is covered to avoid NSIs after injection
• A green cap for sterility and protection before injection
• Compatible with all major injection pen brands

With Ateria^® SafeControl^®, HCPs can keep using a similar injection technique to what they’re used to with traditional pen needles.

A two-part survey looking at safety and pen needle experience showed Ateria^® SafeControl^® is a solution that meets many HCPs’ needs. The findings are published in a white paper, ‘Safety Pen Needles – Take Control.’ The research was conducted by an independent firm for Owen Mumford and included over 200 HCPs. It highlighted practical challenges with passive safety pen needles, such as the safety mechanism activating before injection is complete, causing uncertainty about whether the full dose was given.

Most HCPs taking part recognized that passive safety pen needles improve safety – four out of five agreed that the device increases protection from NSIs. However, the survey also found that 86% agreed safety and control during injection are equally important.

Ateria^® SafeControl^® received positive feedback after being trialed by over 100 HCPs in the research’s second phase. Users felt the device was protective, easy to use, and gave them confidence in delivering the full medication dose.

Follow-up interviews showed 92% were certain they delivered the full dose with the new device, and 75% agreed it offered the right balance of safety and control for drug delivery during injection. Almost three-quarters said that, if they had the choice, they would prefer to use Ateria^® SafeControl^®.

Tracey Sainsbury adds, “We believe Ateria^® SafeControl^® will help solve key challenges for HCPs using passive safety pen needles, giving them confidence they’re providing the best care for their patients.”

Owen Mumford will be exhibiting at the EASD event from September 16^th to 20^th, where Ateria^® SafeControl^® will be available at stand G.04 Hall 2.

ABOUT OWEN MUMFORD

Owen Mumford is a global leader in the design, development, and manufacturing of innovative medical devices used by healthcare professionals and patients. With over 60 years of experience, the company specializes in creating safe, effective drug delivery and blood glucose management devices for diabetes care.

Supported by advanced research with end-users and health professionals, along with extensive design and manufacturing capabilities, Owen Mumford produces industry-leading medical devices used worldwide — exporting over 85% of its products to more than 60 countries.

Named one of The World Economic Forum’s Global Growth Companies, Owen Mumford is a trusted partner to many leading diagnostic and pharmaceutical companies.